Selank Nasal Spray

Selank Nasal Spray is a pre-mixed, ready-to-use intranasal formulation of the synthetic heptapeptide selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.88 Da) at a concentration of 0.15% (1.5 mg/ml), delivered via a calibrated metered-dose pump. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is based on the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg, corresponding to residues 289-292 of the IgG heavy chain) with a C-terminal Pro-Gly-Pro extension derived from the proline-rich peptide family that enhances metabolic stability and CNS penetration.

The intranasal route provides rapid brain delivery via two parallel pathways. The olfactory nerve pathway carries the peptide from the nasal olfactory epithelium along olfactory nerve axons directly into the olfactory bulb and from there to the limbic system (amygdala, hippocampus, nucleus accumbens). The trigeminal nerve pathway delivers peptide via trigeminal nerve branches innervating the nasal mucosa to the brainstem and from there to deeper brain structures. Both pathways bypass the blood-brain barrier entirely. Users report a calm, clear-headed state with reduced anxiety within 15-30 minutes of administration.

The anxiolytic mechanism involves allosteric positive modulation of GABA-A receptors. Electrophysiology studies on hippocampal neurons demonstrated that selank increases the frequency and amplitude of GABA-A-mediated inhibitory postsynaptic currents (IPSCs) without directly activating the receptor. This is mechanistically distinct from benzodiazepines, which bind the alpha/gamma subunit interface and directly potentiate GABA currents, causing sedation, amnesia, and physical dependence. Selank's allosteric modulation enhances inhibitory tone only when and where endogenous GABA is being released, preserving the natural pattern of neural inhibition rather than globally dampening brain activity.

Clinical trials in Russia led to selank's regulatory approval as an anxiolytic nasal spray. In controlled studies involving patients with generalized anxiety disorder, selank nasal spray reduced Hamilton Anxiety Scale (HAM-A) scores by 30-40% over 14 days of twice-daily administration. No sedative effects were observed on any measure, no cognitive impairment was detected on neuropsychological testing, and no withdrawal symptoms occurred after discontinuation. A 6-month follow-up study confirmed no tolerance development. These findings were published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

Beyond anxiolysis, selank modulates multiple neurochemical systems relevant to mood and cognition. It increases BDNF mRNA expression in the hippocampus (confirmed by RT-PCR), which supports neuroplasticity and mood regulation. It inhibits enkephalin-degrading enzymes (enkephalinase/neprilysin), raising endogenous enkephalin tone, which contributes to stress resilience and emotional regulation. It stabilizes serotonin metabolite ratios (5-HIAA/5-HT) in the frontal cortex, normalizing serotonergic transmission that is disrupted in anxiety disorders.

Pharmacokinetically, intranasal selank reaches detectable brain concentrations within 5-10 minutes of administration via the olfactory and trigeminal pathways. The nasal bioavailability to the CNS is estimated at 15-25%. The plasma half-life is approximately 1-3 minutes (rapid proteolytic degradation), but the CNS duration of action is 3-6 hours due to the direct brain delivery route and slower clearance from brain tissue. The metered pump delivers approximately 50-100 mcg per spray.

The nasal spray format requires no reconstitution, no refrigeration during use (stable at room temperature for up to 30 days after opening), and provides consistent dosing through the calibrated pump. For long-term storage, keep sealed vials at 2-8C. Opened sprays should be used within 30 days. The peptide solution is stable at pH 5-6.5.

Safety is well-established through Russian regulatory review and post-marketing surveillance over multiple years. No serious adverse events have been reported at approved doses. The most common side effect is mild nasal discomfort (reported in <5% of patients). No hepatotoxicity, nephrotoxicity, cardiovascular effects, or hormonal changes have been observed. Selank does not impair driving ability or reaction time. It does not interact with alcohol in the potentiating manner that benzodiazepines do. No mutagenicity in preclinical testing.